title: A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques.
abstract: Chronic hepatitis C virus (HCV) infection, with its cohort of life-threatening complications, affects more than 200 million persons worldwide and has a prevalence of more than 10% in certain countries. Preventive and therapeutic vaccines against HCV are thus much needed. Neutralizing antibodies (NAbs) are the foundation for successful disease prevention for most established vaccines. However, for viruses that cause chronic infection such as HIV or HCV, induction of broad NAbs from recombinant vaccines has remained elusive. We developed a vaccine platform specifically aimed at inducing NAbs based on pseudotyped virus-like particles (VLPs) made with retroviral Gag. We report that VLPs pseudotyped with E2 and/or E1 HCV envelope glycoproteins induced high-titer anti-E2 and/or anti-E1 antibodies, as well as NAbs, in both mouse and macaque. The NAbs, which were raised against HCV 1a, cross-neutralized the five other genotypes tested (1b, 2a, 2b, 4, and 5). Thus, the described VLP platform, which can be pseudotyped with a vast array of virus envelope glycoproteins, represents a new approach to viral vaccine development.
authors.affiliation: Epixis S.A., F-69007 Lyon, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Garrone
authors.forename: Anne-Catherine
authors.initials: AC
authors.lastname: Fluckiger
authors.forename: Philippe E
authors.initials: PE
authors.lastname: Mangeot
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Gauthier
authors.forename: Pia
authors.initials: P
authors.lastname: Dupeyrot-Lacas
authors.forename: Jimmy
authors.initials: J
authors.lastname: Mancip
authors.forename: Arnaud
authors.initials: A
authors.lastname: Cangialosi
authors.forename: Isaure
authors.initials: I
authors.lastname: Du Chéné
authors.forename: Roger
authors.initials: R
authors.lastname: LeGrand
authors.forename: Isabelle
authors.initials: I
authors.lastname: Mangeot
authors.forename: Dimitri
authors.initials: D
authors.lastname: Lavillette
authors.forename: Bertrand
authors.initials: B
authors.lastname: Bellier
authors.forename: François-Loic
authors.initials: FL
authors.lastname: Cosset
authors.forename: Frederic
authors.initials: F
authors.lastname: Tangy
authors.forename: David
authors.initials: D
authors.lastname: Klatzmann
authors.forename: Charlotte
authors.initials: C
authors.lastname: Dalba
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000096:biosynthesis*; D003429:Cross Reactions; D016174:Hepacivirus / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000096:biosynthesis; D008251:Macaca; D051379:Mice; D008969:Molecular Sequence Data; D014764:Viral Proteins / Q000276:immunology*; D014771:Virion / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D018937:Hepatitis C Antibodies; D014764:Viral Proteins